New hope for pancreatic cancer: combo therapy enters phase 2 trial
Disease control
Not yet recruiting
This study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemo…
Phase: PHASE2 • Sponsor: Nelum Corp • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC